Germany
· Delayed Price · Currency is EUR OraSure Technologies Company Description
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic and specimen collection devices and products in the United States, Europe, Africa, and internationally.
It offers OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples.
In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community.
Further, the company offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets.
OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
| Country | United States |
| Founded | 2000 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 501 |
| CEO | Carrie Eglinton Manner |
Contact Details
Address: 220 East First Street Bethlehem, Delaware 18015 United States | |
| Phone | 610 882 1820 |
| Website | orasure.com |
Stock Details
| Ticker Symbol | EP3 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Carrie Eglinton Manner | Chief Executive Officer |
| Kenneth McGrath | Chief Financial Officer |
| Jason Plagman | Head of Investor Relations |